Skip to main navigation Skip to search Skip to main content

Does intravesical Bacillus Calmette-Guérin for bladder cancer protect from COVID-19?

Anastasia MacDonald, Lexia Bao, Vahid Mehrnoush, Asmaa Ismail, Livio Di Matteo, Ahmed Zakaria, Hazem Elmansy, Peter Black, Ahmed Kotb

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The study aimed to correlate the history of intravesical BCG as well as infantile BCG immunization with the incidence and severity of COVID-19 infection. Methods: Retrospective data collection of patients with high-risk non muscle invasive bladder cancer (NMIBC) from two Canadian centers. Data collection included a history of BCG instillation, infantile immunization, and the development of COVID-19 infection. Admission and/ or mortality because of COVID-19 was reported. Results: We could include data from 348 patients: including 188 and 160 patients from Ontario and British Columbia respectively. COVID-19 affected 15% of these patients. Intravesical BCG was used in 44% of these patients. Intravesical BCG and/or infantile BCG immunization did not correlate with the incidence of COVID-19 infection. Conclusions: Previous intravesical BCG and/ or a history of infantile BCG vaccination were not more/ less frequent in patients who had COVID-19 infection.

Original languageEnglish (US)
JournalArchivio Italiano di Urologia e Andrologia
Volume96
Issue number2
DOIs
StatePublished - 2024

Keywords

  • BCG
  • Bladder cancer
  • COVID-19

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Does intravesical Bacillus Calmette-Guérin for bladder cancer protect from COVID-19?'. Together they form a unique fingerprint.

Cite this